# Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

> **NCT02413138** · PHASE2,PHASE3 · TERMINATED · sponsor: **Versartis Inc.** · enrollment: 41 (actual)

## Conditions studied

- Pediatric Growth Hormone Deficiency
- Growth Disorders

## Interventions

- **DRUG:** Somavaratan (VRS-317)

## Key facts

- **NCT ID:** NCT02413138
- **Lead sponsor:** Versartis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-08
- **Primary completion:** 2017-11-30
- **Final completion:** 2017-11-30
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved
- **Last updated:** 2022-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413138, "Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02413138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*